Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001837 · ClinicalTrials.gov registry record
Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients
A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 60
- Enrollment target
NCT00001837 is a clinical trial that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 60 participants.
The verdict
NCT00001837 has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
This research study is designed to work in cooperation with another study being conducted by the National Cancer Institute. The National Cancer Institute (NCI) is studying the effects of a drug called raloxifene on premenopausal women believed to have a high risk of developing breast cancer (98-C-0123). In this study, researchers are interested in learning about the effects of raloxifene on the uterus and ovaries of the women participating in the NCI study. To do this researchers plan to conduct ultrasounds on the patients enrolled in the NCI study. In addition researchers plan to take samples of the lining of the uterus in these patients (endometrial biopsy) if found to be necessary. The purpose of this study is to determine the reproductive effects of raloxifene on women who have normal functioning ovaries by taking ultrasounds of the ovaries and lining of the uterus (endometrium).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1998-11 |
| Est. Completion | 2005-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001837
The ClinicalTrials.gov registry entry for NCT00001837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001837 about?
NCT00001837 is a clinical study titled "Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients". This research study is designed to work in cooperation with another study being conducted by the National Cancer Institute. The National Cancer Institute (NCI) is studying the effects of a drug called raloxifene on premenopausal women believed to have a high risk of developing breast cancer (98-C-01...
What is the current status of trial NCT00001837?
This trial is currently completed. The enrollment target is 60 participants. The study started on 1998-11. Estimated completion is 2005-10.
Who is sponsoring clinical trial NCT00001837?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.